Available technologies

Portfolio of human colorectal adenocarcinomas

Reference number: 5129

A portfolio of human colorectal adenocarcenoma cell lines including primary cell lines isolated from patients (of various Duke's stages and histological grades) in addition to cloned cells lines genetically modified to highly express alpha integrin domains.

Technology overview


Six cell lines from primary human colorectal adenocarcinomas were established from surgical specimens without the use of 'feeder' cells, 'conditioned' medium or passage of cells in nude mice. The six cell lines exhibit considerable variation in morphology, CEA secretion and tumourigenicity in nude mice. At least two of the lines retain some of the differentiated characteristics of colorectal epithelium. HRA-19 has stem cell properties and undergoes a multilineage differentiation in serum free medium.


HRA-19a1.1 is a clone derived from HRA-19. The HRA-19a1.1 cell line was transfected with alpha integrin domain coding plasmids to create cell lines highly expressing alpha2 or alpha2 and alpha 1 integrin. In experiments, cell lines expressing alpha2 showed a significantly increased endrocrine and mucous cell lineage commitment relative to the parent cell line.


  • Cell lines are invaluable tools for biomedical research.
  • Cancer cell lines are the foundation of cancer biology and the quest for drug treatments.
  • Adenocarcinoma is a cancer of the epithelium (including colon) and originates in glandular tissue, such as skin surface layer and glands.

Purchasing these cell lines

This portfolio of human colorectal adenocarcenoma cell lines is available from Public Health England ECCAC


Purchase directly from ECCAC


    S C Kirkland and H Ying (2008) α2β1 Integrin regulates lineage commitment in multipotent human colorectal cancer cells, J Biol Chem, 283(41): 27612-27619.

    Inventor information

    Dr Sue Kirkland

    Download datasheet


    Alexandra Skeaping

    Industry Partnerships and Commercialisation Officer, Medicine


    +44 (0)20 7594 7021

    Contact us about this technology

    Subscribe for Licensing Opportunities updates
    Keep up to date with new technologies and licensing opportunities coming out of Imperial College London